https://www.maxproventures.com/news/advaxis-inc-announces-20-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2025-09-09 https://www.maxproventures.com/news/taho-pharmaceuticals-reports-positive-results-from-pivotal-study-of-tah3311 2025-09-09 https://www.maxproventures.com/news/anbogen-therapeutics-inc-wins-the-21st-national-innovation-award 2025-09-09 https://www.maxproventures.com/news/apollomics-appoints-matthew-plunkett-ph-d-as-chief-financial-officer 2025-09-09 https://www.maxproventures.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016 2025-09-09 https://www.maxproventures.com/news/anbogen-secures-12-5-million-usd-in-series-a-funding-advancing-precision-oncology-drug-development 2025-09-09 https://www.maxproventures.com/news/apollomics-completes-enrollment-in-phase-3-bridging-study-of-uproleselan-in-chinese 2025-09-09 https://www.maxproventures.com/news/apollomics-presents-interim-data-from-two-ongoing-phase-2-clinical-trials-with-vebreltinib 2025-09-09 https://www.maxproventures.com/news/arthrosi-to-present-positive-phase-2-data-for-its-novel-selective-urat1 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-presentation-of-vebreltinib-data 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-the-first-approval-of-vebreltinib-for-met-exon-14-skip-non-small 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-two-new-cohorts-in-global-phase-2-sparta-study-of-vebreltinib 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-report-of-activity-of-vebreltinib-in-glioblastoma 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-efficacy-of-vebreltinib-in-nsclc 2025-09-09 https://www.maxproventures.com/news/apollomics-announces-presentations-of-vebreltinib-data-at-esmo-2023 2025-09-09 https://www.maxproventures.com/news/apollomics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference 2025-09-09 https://www.maxproventures.com/news/arthrosi-therapeutics-ar882-prepares-to-enter-into-global-phase-3-study 2025-09-09 https://www.maxproventures.com/news/arthrosi-secures-75m-in-series-d-financing 2025-09-09 https://www.maxproventures.com/news/apollomics-co-founder-and-president-sanjeev-redkar-ph-d-to-speak-at-23rd 2025-09-09 https://www.maxproventures.com/news/apollomics-a-company-developing-novel-oncology-therapies-to-address 2025-09-09 https://www.maxproventures.com/news/arthrosi-announces-positive-topline-results-for-ar882-phase-2b-study 2025-09-09 https://www.maxproventures.com/news/apollomics-inc-receives-fda-orphan-drug-designation-for-vebreltinib-apl-101-for-treatment 2025-09-09 https://www.maxproventures.com/news/maxpro-capital-acquisition-corp-confirms-additional-funding-and-extension-of-deadline 2025-09-09 https://www.maxproventures.com/news/maxpro-capital-acquisition-corp-announces-extension-to-deadline-to-complete-business-combination 2025-09-09 https://www.maxproventures.com/news/apollomics-inc-a-late-stage-clinical-biopharmaceutical-company-to-be-listed-on-nasdaq 2025-09-09 https://www.maxproventures.com/news/arthrosi-completes-ar882-phase-2b-study-enrollment 2025-09-09 https://www.maxproventures.com/news/acepodia-raises-109-million-series-c-financing-to-advance-development 2025-09-09 https://www.maxproventures.com/news/maxpro-capital-acquisition-corp-announces-the-separate-trading-of-its-class-a-common-stock 2025-09-09 https://www.maxproventures.com/news/act-genomics-joins-force-with-sanomics 2025-09-09 https://www.maxproventures.com/news/syneurx-announces-oral-covid-19-twindemic-antiviral-drug 2025-09-09 https://www.maxproventures.com/news/acepodia-strengthens-board-of-directors-and-scientific-advisory-board-with-key-appointments 2025-09-09 https://www.maxproventures.com/news/arthrosi-presents-ar882-posters-at-acr-2021 2025-09-09 https://www.maxproventures.com/news/eirgenix-completed-its-ntd-5-03-billion-private-placement-on-the-fifteenth-of-october 2025-09-09 https://www.maxproventures.com/news/arthrosi-appoints-robert-thomas-keenan-md-mph-mba-as-chief-medical-officer 2025-09-09 https://www.maxproventures.com/news/maxpro-capital-acquisition-corp-announces-closing-of-initial-public-offering 2025-09-09 https://www.maxproventures.com/news/maxpro-capital-acquisition-corp-announces-pricing-of-90-000-000-initial-public-offering 2025-09-09 https://www.maxproventures.com/news/cerbact-asia-holds-ribbon-cutting-to-celebrate-new-immuno-oncology-centre-of-excellence 2025-09-09 https://www.maxproventures.com/news/acepodia-presents-positive-interim-phase-1-feasibility-data-for-antibody-cell-effector 2025-09-09 https://www.maxproventures.com/news/acepodia-to-present-data-from-preclinical-and-phase-1-studies-of-ace1702 2025-09-09 https://www.maxproventures.com/news/cerba-research-and-act-genomics-announce-strategic-joint-venture-cerbact-asia 2025-09-09 https://www.maxproventures.com/news/arthrosi-establishes-joint-venture-in-china-to-accelerate-development-of-innovative-drug-portfolio 2025-09-09 https://www.maxproventures.com/news/spac-jade-mountain-acquisition-files-for-a-100-million-ipo-targeting-health-and-tech 2025-09-09 https://www.maxproventures.com/news/eirgenix-achieves-the-fourth-milestone-of-its-trastuzumab-biosimilar-licensing-agreement 2025-09-09 https://www.maxproventures.com/news/acepodia-publishes-preclinical-data-on-novel-off-the-shelf-natural-killer-cell-therapy-ace1702 2025-09-09 https://www.maxproventures.com/news/arthrosi-therapeutics-inc-announces-impressive-phase-2a-study-results-for-gout-patients 2025-09-09 https://www.maxproventures.com/news/advaxis-presents-updated-clinical-data-from-ongoing-phase-1-2-trial-of-adxs-503-in-nsclc 2025-09-09 https://www.maxproventures.com/news/act-genomics-signs-mou-with-hku-space-on-training-healthcare-professionals 2025-09-09 https://www.maxproventures.com/news/the-return-of-jimmy-lai-jimmy-lai-cfo-acepodia 2025-09-09 https://www.maxproventures.com/news/acepodia-presents-data-on-its-allogeneic-natural-killer-like-gamma-delta-t-cell-therapy-ace1831 2025-09-09 https://www.maxproventures.com/news/acepodia-appoints-thorsten-graef-m-d-ph-d-as-chief-medical-officer-and-michael-brock 2025-09-09 https://www.maxproventures.com/news/arthrosi-s-new-molecule-ar882-for-gout-shows-blockbuster-potential 2025-09-09 https://www.maxproventures.com/news/genscript-launches-research-grade-lentiviral-vector-packaging-service 2025-09-09 https://www.maxproventures.com/news/genscript-parkway-laboratories-and-diagnostics-development-dxd-hub-collaborate 2025-09-09 https://www.maxproventures.com/news/hong-hai-foxconn-founder-terry-guo-announces-investment-to-accelerate-eirgenix-s-global-expansion 2025-09-09 https://www.maxproventures.com/news/advaxis-to-present-at-the-american-society-of-clinical-oncology-asco-2021-annual-meeting 2025-09-09 https://www.maxproventures.com/news/advaxis-announces-receipt-of-second-milestone-payment-under-adxs-her2 2025-09-09 https://www.maxproventures.com/news/advaxis-presents-translational-biomarker-data-from-ongoing-adxs-503-phase-1-2-lung-cancer 2025-09-09 https://www.maxproventures.com/news/advaxis-announces-agreement-with-columbia-university-irving-medical-center 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-announces-dosing-of-first-patient-in-phase-2-3-clinical-trial-of-fp-025 2025-09-09 https://www.maxproventures.com/news/us-fda-approves-syneurx-s-ind-application-for-phase-clinical-trial-for-adult-patients 2025-09-09 https://www.maxproventures.com/news/positive-phase-iii-clinical-results-for-eirgenix-s-proposed-trastuzumab-biosimilar 2025-09-09 https://www.maxproventures.com/news/taiwan-s-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies 2025-09-09 https://www.maxproventures.com/news/advaxis-to-present-at-the-american-association-for-cancer-research-aacr-2021-annual-meeting 2025-09-09 https://www.maxproventures.com/news/tfda-approves-syneurx-to-conduct-phasa-b-clinical-trials-for-its-drug-candidates 2025-09-09 https://www.maxproventures.com/news/polaris-phase-iii-interim-analysis-of-lung-mesothelioma-carcinoma 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-enters-exclusive-license-agreement-with-intas 2025-09-09 https://www.maxproventures.com/news/naben-the-ultimate-and-supreme-sodium-benzoate 2025-09-09 https://www.maxproventures.com/news/2-000-per-dose-cell-therapy-in-the-clinic 2025-09-09 https://www.maxproventures.com/news/a-novel-endogenous-cd16-expressing-natural-killer-cell-for-cancer-immunotherapy 2025-09-09 https://www.maxproventures.com/news/advaxis-reports-fiscal-year-2020-financial-results-and-provides-a-business-update 2025-09-09 https://www.maxproventures.com/news/advaxis-announces-receipt-of-funding-milestone-payment-under-adxs-her2-licensing 2025-09-09 https://www.maxproventures.com/news/acepodia-s-approach-to-acc-car-manufacturing-scalability 2025-09-09 https://www.maxproventures.com/news/taiwan-healthcare-data-preservation-platform-initiative 2025-09-09 https://www.maxproventures.com/news/biopharma-executive-perspectives-on-2021 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-announces-completion-of-us-47-million-financing 2025-09-09 https://www.maxproventures.com/news/summit-study-provided-another-treatment-options-for-nsclc-egfr-exon-18-mutations-patients 2025-09-09 https://www.maxproventures.com/news/novel-resistance-mechanism-for-savolitinib-in-met-amplified-gastric-cancer 2025-09-09 https://www.maxproventures.com/news/clinical-trial-results-of-tazemetostat-for-ini1-smarcb1-negative-epithelioid-sarcoma 2025-09-09 https://www.maxproventures.com/news/advaxis-announces-listing-transfer-to-nasdaq-capital-mark 2025-09-09 https://www.maxproventures.com/news/eirgenix-at-2020-healthcare-expo-taiwan-december-3-6-2020 2025-09-09 https://www.maxproventures.com/news/advaxis-inc-announces-closing-of-9-2-million-public-offering 2025-09-09 https://www.maxproventures.com/news/advaxis-inc-announces-pricing-of-8-million-public-offering 2025-09-09 https://www.maxproventures.com/news/ch5126766-is-a-novel-potential-treatment-for-ras-raf-mutant-cancers 2025-09-09 https://www.maxproventures.com/news/adagrasib-mrtx849-showed-efficacy-and-safety-in-krasg12c-nsclcs-from-krystal-1-study 2025-09-09 https://www.maxproventures.com/news/a-new-oral-serd-drug-sar439859-shown-the-anti-tumor-activity-in-er-her2-breast-cancer 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-enters-exclusive-license-agreement-with-gensci 2025-09-09 https://www.maxproventures.com/news/acepodia-to-present-late-breaking-poster-presentation-supporting-the-potential-of-its-nk-cell 2025-09-09 https://www.maxproventures.com/news/arthrosi-therapeutics-released-phase-2-clinical-data-of-ar882 2025-09-09 https://www.maxproventures.com/news/advaxis-presents-updated-data-from-ongoing-adxs-503-phase-1-2-lung-cancer-trial 2025-09-09 https://www.maxproventures.com/news/eirgenix-completes-neoadjuvant-treatment-and-surgery-for-last-patient-in-phase-iii-clinical-trial 2025-09-09 https://www.maxproventures.com/news/genscript-receives-fda-emergency-use-authorization-for-world-s-first-sars-cov-2-neutralizing 2025-09-09 https://www.maxproventures.com/news/acepodia-to-deliver-late-breaking-poster-presentation-at-the-society-for-immunotherapy 2025-09-09 https://www.maxproventures.com/news/advaxis-adxs-503-hot-lung-demonstrates-pronounced-and-sustained-tumor-control 2025-09-09 https://www.maxproventures.com/news/an-egfr-met-bispecific-antibody-amivantamab-jnj-372-combine-with-3rd-generation 2025-09-09 https://www.maxproventures.com/news/poziotinib-showed-potential-in-treating-nsclc-patients-harboring-an-erbb2-exon-20 2025-09-09 https://www.maxproventures.com/news/the-biomarker-exploratory-analyzed-results-of-the-phase-3-javelin-bladder-100-trial 2025-09-09 https://www.maxproventures.com/news/acepodia-to-present-at-the-7th-annual-china-healthcare-summit 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-announces-nda-for-camcevi-42mg-accepted-for-review-by-the-fda 2025-09-09 https://www.maxproventures.com/news/polaris-group-signs-collaboration-agreement-with-nanotein-technologies-inc 2025-09-09 https://www.maxproventures.com/news/advaxis-inc-adopts-limited-duration-stockholder-rights-plan 2025-09-09 https://www.maxproventures.com/news/vstrip-covid-19-antigen-rapid-test-validated-and-approved-in-india 2025-09-09 https://www.maxproventures.com/news/advaxis-reports-third-quarter-ended-july-31-2020-financial-results-and-provides 2025-09-09 https://www.maxproventures.com/news/advaxis-announces-fda-clearance-of-new-ind-for-adxs-504-for-treatment-of-prostate-cancer 2025-09-07 https://www.maxproventures.com/news/ensartinib-a-new-tki-inhibitor-prolonged-pfs-in-alk-nsclc-patients 2025-09-09 https://www.maxproventures.com/news/olaparib-and-durvalumab-combination-showed-promising-results-in-her2-negative 2025-09-09 https://www.maxproventures.com/news/a-case-series-study-of-cancers-with-nrg1-gene-fusion 2025-09-09 https://www.maxproventures.com/news/2020-healthcare-expo-taiwan-eirgenix-inc-your-reliable-biologics-partner 2025-09-09 https://www.maxproventures.com/news/jhl-teams-up-with-adimmune-for-covid-19-vaccine-production 2025-09-09 https://www.maxproventures.com/news/foresee-pharmaceuticals-to-present-at-the-2020-fanconi-anemia-scientific-symposium 2025-09-07 https://www.maxproventures.com/news/ace1702-a-potent-and-off-the-shelf-onk-cell-therapy-product 2025-09-09 https://www.maxproventures.com/news/polaris-announces-to-enroll-the-first-patient-of-phase-ib-clinical-trial-in-gbm 2025-09-09 https://www.maxproventures.com/news/from-natural-killer-cells-to-off-the-shelf-car-ts-biopharma-targets-cancer-with-next-gen 2025-09-09 https://www.maxproventures.com/news/eirgenix-achieves-the-third-milestone-of-its-trastuzumab-biosimilar-licensing-agreement 2025-09-09 https://www.maxproventures.com/news/acepodia-strengthens-management-team-with-appointments-of-biotech-industry-veterans 2025-09-09 https://www.maxproventures.com/news/innatoss-laboratories-launches-neutralizing-antibody-public-testing-service-for-sars-cov-2-in-europe-using-genscript%E2%80%99s-cpass%E2%84%A2-kit 2025-09-08 https://www.maxproventures.com/news/esr1-mutation-as-a-prediction-marker-for-1st-line-ai-plus-cdk4-6-inhibitor-in-hr-breast-cancer 2025-09-09 https://www.maxproventures.com/news/vstrip%C2%AE-covid-19-antigen-rapid-test-approved-by-taiwan-fda 2025-09-07 https://www.maxproventures.com/news/a-new-idh1%2F2-inhibitor-for-mutated-idh1%2F2-low-grade-glioma 2025-09-07 https://www.maxproventures.com/news/acepodia-initiates-a-phase-1-clinical-trial-evaluating-allogeneic-nk-cell-therapy-ace1702-for-treatment-of-solid-tumors 2025-09-07 https://www.maxproventures.com/news/brief-arthrosi-therapeutics-inc-says-has-raised-%248.5-million-in-equity-financing 2025-09-07 https://www.maxproventures.com/news/jhl-biotech-doses-first-patients-in-denosumab-trial 2025-09-07 https://www.maxproventures.com/news/polaris-group-announces-officially-secured-usd-100-million-new-funding 2025-09-09 https://www.maxproventures.com/news/u-s-fda-approves-generic-versions-of-novartis-blockbuster-ms-treatment 2025-09-09 https://www.maxproventures.com/news/boarding-director-re-election-obm-ai-comes-back-strong-to-biotaiwan 2025-09-09 https://www.maxproventures.com/news/polaris-group-adi-peg20-on-the-cover-of-aacr-journals 2025-09-09 https://www.maxproventures.com/news/blackstone-invests-large-stake-in-hec-pharm 2025-09-07 https://www.maxproventures.com/news/original-biomedicals-6483-sings-up-the-memorandum-of-understanding-with-nanoray-biotech-co-ltd 2025-09-09 https://www.maxproventures.com/news/original-biomedicals-sings-up-product-sales-and-development-agreement-with-beijing-meone-pharma. 2025-09-07 https://www.maxproventures.com/news/first-five-subjects-randomized-in-syneurx%E2%80%99-snd12-phaseiib%2Fiii-study-of-clozaben%C2%AE%2C-a-novel-traetment-for-refractory-schizophrenia 2025-09-07 https://www.maxproventures.com/news/first-three-subjects-randomized-in-syneurx%E2%80%99s-snd13-phase-iib%2Fiii-naben%C2%A9-schizophrenia-trial 2025-09-07 https://www.maxproventures.com/news/five-questions-with-immunwork 2025-09-06 https://www.maxproventures.com/news/fda-approves-syneurx%E2%80%99s-ind-application-for-late-phase-clinical-development-of-a-mild-dementia-treatment 2025-09-07